LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, proudly announces its 25th anniversary. For a quarter of a century, ChromaDex has been at the forefront of analytical chemistry and scientific innovation, dedicated to unlocking the full potential of NAD+ to promote healthy aging and enhance the quality of life for people around the world..

洛杉矶——（商业新闻短讯）——专注于健康衰老的烟酰胺腺嘌呤二核苷酸（NAD+）研究全球权威机构ChromaDex Corp.（纳斯达克：CDXC）骄傲地宣布成立25周年。四分之一个世纪以来，ChromaDex一直处于分析化学和科学创新的前沿，致力于释放NAD+的全部潜力，以促进健康老龄化，提高全世界人民的生活质量。。

To celebrate this milestone, ChromaDex is offering an exclusive 25% off a lifelong subscription to Tru Niagen®, the number one NAD+ supplement for healthy aging in the United States⤉ (additional details below).

为了庆祝这一里程碑，ChromaDex提供终身订阅Tru Niagen®的独家七五折优惠，Tru Niagen®是美国健康老龄化的头号NAD+补充剂（更多详细信息见下文）。

A Legacy of Innovation and Leadership

创新和领导力的遗产

Founded in 1999, ChromaDex’s journey began in the analytical testing space and supplying reference standard materials to researchers and other companies. ChromaDex then transitioned its business to developing and selling proprietary ingredients in the food and dietary supplement space.

ChromaDex成立于1999年，其旅程始于分析测试领域，为研究人员和其他公司提供参考标准材料。然后，ChromaDex将其业务转变为在食品和膳食补充剂领域开发和销售专有成分。

In 2004, Dr. Charles Brenner discovered the breakthrough that illuminated the process by which nicotinamide riboside (NR) increases cellular NAD+ levels. ChromaDex licensed the patents behind Dr. Brenner’s research in 2012, making this revolutionary science accessible worldwide. A year later, the company launched Niagen®, the world’s first patented form of NR and the most efficient, high-quality NAD+ precursor available..

2004年，Charles Brenner博士发现了一项突破，阐明了烟酰胺核苷（NR）增加细胞NAD+水平的过程。ChromaDex于2012年授权了Brenner博士研究背后的专利，使这项革命性的科学可以在全球范围内获得。。。

Niagen has since become both the cornerstone for independent preclinical and clinical NAD+ research and the hero ingredient in the company’s dietary supplement line, available to consumers under the brand Tru Niagen. Today, Tru Niagen is the number one NAD+ supplement for healthy aging in the U.S., with over 8 million bottles sold⤉..

自那时以来，尼亚根已成为独立临床前和临床NAD+研究的基石，也是该公司膳食补充剂系列中的英雄成分，可供Tru Niagen品牌的消费者使用。。。

Just this year, ChromaDex marked yet another milestone as it unveiled the first-of-its-kind pharmaceutical grade Niagen (patented nicotinamide riboside chloride or NRCl), branded Niagen+™. Available as Niagen IV and injections exclusively at clinics with a prescription, Niagen IV represents a significant advancement in intravenous therapy..

就在今年，ChromaDex标志着又一个里程碑，它推出了第一款药物级Niagen（专利烟酰胺核苷氯化物或NRCl），品牌为Niagen+™。尼亚根IV（Niagen IV）可作为尼亚根IV（Niagen IV）并仅在诊所按处方注射，它代表了静脉治疗的重大进步。。

Rob Fried, CEO of ChromaDex and Founder of Tru Niagen, commented, 'Frank Jaksch founded ChromaDex as a reference standards business, a legacy that proudly endures today, reminding us that performing at the highest scientific and professional standard is in our DNA. We believe ChromaDex remains the gold standard in quality, efficacy, safety, and ethical business practices.”.

ChromaDex首席执行官兼Tru Niagen创始人罗伯·弗里德（RobFried）评论道：“弗兰克·雅克希（FrankJaksch）将ChromaDex创建为一家参考标准企业，这是一项值得骄傲地延续至今的遗产，它提醒我们，在最高科学和专业标准下的表现是我们的DNA。我们相信ChromaDex仍然是质量、功效、安全性和道德商业实践的黄金标准。”。

The Gold Standard in Scientific Excellence and Quality

Over the past 25 years, ChromaDex has established itself as the gold standard in scientific rigor and quality. With more than 275 research agreements globally, 175+ peer-reviewed publications, and over 30 human clinical studies featuring Niagen, the ChromaDex External Research Program (CERP™) has been instrumental in advancing the scientific understanding of NAD+ and its role in age-related health conditions..

在过去的25年中，ChromaDex已成为科学严谨性和质量的金标准。ChromaDex外部研究计划（CERP™）在全球范围内达成了275多项研究协议，175多篇同行评审的出版物，以及30多项以尼亚根为特征的人体临床研究，有助于增进对NAD+及其在与年龄有关的健康状况中的作用的科学理解。。

CERP, which celebrated its 10th anniversary just last year, has been a driving force behind this success, fostering collaborations with over 200 institutions, including the Mayo Clinic, the National Institute on Aging, and Harvard University. This program has generated over $100 million in third-party research for age and non-age-related conditions, such as inflammation, Ataxia Telangiectasia, Parkinson’s disease, Alzheimer’s disease, and heart disease..

去年刚刚庆祝成立10周年的CERP一直是这一成功的驱动力，它促进了与200多家机构的合作，其中包括梅奥诊所、国家老龄研究所和哈佛大学。该项目为年龄和非年龄相关疾病（如炎症、共济失调毛细血管扩张症、帕金森病、阿尔茨海默病和心脏病）的第三方研究产生了超过1亿美元的资金。。

The company’s robust patent portfolio now includes over 90 patents related to NAD+ precursors, including NR, NRH, NAR, and NMNH.

该公司强大的专利组合现在包括90多项与NAD+前体相关的专利，包括NR、NRH、NAR和NMNH。

Dedicated to Healthy Aging for All

致力于全民健康老龄化

A never-before-seen 25% discount on lifelong subscriptions to Tru Niagen is being offered to commemorate this celebration, along with a 25% discount on one-time purchases until September 12, 2024 at truniagen.com. This special promotion reflects ChromaDex’s commitment to making the benefits of NAD+ supplementation accessible to as many people as possible..

为了纪念这一庆祝活动，truniagen网站提供了前所未有的终身订阅25%折扣，同时在truniagen.com网站上提供了2024年9月12日之前一次性购买的25%折扣。这一特别促销活动反映了ChromaDex致力于让尽可能多的人获得NAD+补充剂的好处。。

For additional information on ChromaDex, visit www.chromadex.com.

有关ChromaDex的更多信息，请访问www.ChromaDex.com。

⤉Based on the top-selling dietary supplement brands by revenue per the largest US ecommerce marketplace [identified through a search dated March 1, 2023 – Feb. 29, 2024 using “NAD precursors”

⤉根据美国最大电子商务市场收入最高的膳食补充剂品牌[通过2023年3月1日至2024年2月29日使用“NAD前体”进行的搜索确定]

Forward Looking Statements:

前瞻性声明：

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to sales and marketing activity, and ongoing research and development efforts.

本版本包含经修订的《1933年证券法》第27A节和经修订的《1934年证券交易法》第21E节所指的前瞻性声明，包括与销售和营销活动以及正在进行的研究和开发工作有关的声明。

Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as 'expects,' 'anticipates,' 'intends,' 'estimates,' 'plans,' 'potential,' 'possible,' 'probable,' 'believes,' 'seeks,' 'may,' 'will,' 'should,' 'could' or the negative of such terms or other similar expressions.

。

Risks that contribute to the uncertain nature of these forward-looking statements include the impact of the COVID-19 pandemic on our business and the global economy; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition.

导致这些前瞻性声明不确定性的风险包括新型冠状病毒对我们的业务和全球经济的影响；我们的经营亏损历史以及需要获得额外融资；我们产品销售的增长和盈利能力；我们保持销售、营销和分销能力的能力；改变消费者对我们产品的看法；我们依赖单一或有限数量的第三方供应商；以及与我们的业务和财务状况相关的风险和不确定性。

More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov.

有关ChromaDex和可能影响前瞻性陈述实现的风险因素的更多详细信息，请参阅ChromaDex截至2023年12月31日的10-K表年度报告、ChromaDex的10-Q表季度报告以及ChromaDex提交给SEC的其他文件，其副本可从SEC网站www.SEC.gov获得。

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ ma.

提醒读者不要过度依赖这些前瞻性声明，这些声明仅在本协议签署之日起生效，实际结果可能会有所不同。

About ChromaDex:

关于ChromaDex：

ChromaDex Corp. (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, comprised of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+.

ChromaDex Corp.（纳斯达克：CDXC）是烟酰胺腺嘌呤二核苷酸（NAD+）的全球权威，专注于健康衰老科学。ChromaDex团队由世界著名科学家组成，与来自全球知名大学和研究机构的独立研究人员合作，以揭示NAD+的全部潜力。

A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality..

NAD+是人体每个细胞中发现的一种重要辅酶，随着年龄的增长和暴露于其他日常压力源而下降。NAD+耗竭是与年龄相关的健康和活力变化的原因。。

Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available.

。

Niagen is the active ingredient in ChromaDex’s consumer products, sold as the brand Tru Niagen®, the number one healthy-aging NAD+ supplement in the United States†. Clinically proven to increase NAD+ levels, Tru Niagen is helping people around the world transform the way they age (available at www.truniagen.com)..

Niagen是ChromaDex消费品中的活性成分，以Tru Niagen®品牌出售，Tru Niagen®是美国排名第一的健康衰老NAD+补充剂†。临床证明，Tru Niagen可以提高NAD+水平，正在帮助世界各地的人们改变他们的衰老方式（可从www.truniagen.com获得）。。

ChromaDex’s robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com, to which ChromaDex regularly publishes copies of its press releases, news, and financial information.

ChromaDex强大的专利组合保护NR和其他NAD+前体。ChromaDex在www.ChromaDex.com上维护一个网站，ChromaDex定期向其发布新闻稿、新闻和财务信息的副本。

†Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 3/1/2023-2/29/2024).

†根据美国最大电子商务市场（截至2023年3月1日至2024年2月29日）收入最高的膳食补充剂品牌。